| Literature DB >> 33801613 |
Paola Modesto1, Chiara Grazia De Ciucis1, Walter Vencia1, Maria Concetta Pugliano1, Walter Mignone2, Enrica Berio2, Chiara Masotti3, Carlo Ercolini3, Laura Serracca3, Tiziana Andreoli4, Monica Dellepiane4, Daniela Adriano5, Simona Zoppi5, Daniela Meloni5, Elisabetta Razzuoli1.
Abstract
Yersinia enterocolitica (Ye) is a very important zoonosis andwild boars play a pivotal role in its transmission. In the last decade, the wild boar population has undergone a strong increase that haspushed them towards urbanized areas, facilitating the human-wildlife interface and the spread of infectious diseases from wildlife to domestic animals and humans. Therefore, it is important to know the serotype, antimicrobial resistance and presence of pathogenicity genes of Yersinia enterocolitica (Ye) isolated in species. From 2013 to 2018, we analyzed the liver of 4890 wild boars hunted in Liguria region; we isolated and serotyped 126 Ye positive samples. A decisive role in the pathogenicity is given by the presence of virulence genes; in Ye isolated we found ystB (~70%), ymoA (45.2%), ail (43.6%) and ystA (~20%). Moreover, we evaluated the susceptibility at various antimicrobic agents (Ampicillin, Chloramphenicol, Enrofloxacin, Gentamicin, Kanamycin, Trimethoprim-Sulfamethoxazole, Sulfisoxazole, Ceftiofur and Tetracycline). The antibiotic resistance was analyzed, and we found a time-dependent increase. It is important to shed light on the role of the wild boars as a reserve of potentially dangerous diseases for humans, and also on the antibiotic resistance that represents a public health problem.Entities:
Keywords: Yersinia enterocolitica; antibiotic-resistance; biotypes; pathogenicity; wild boar
Year: 2021 PMID: 33801613 PMCID: PMC8065425 DOI: 10.3390/pathogens10040398
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817
Figure 1Percentage of Yersinia enterocolitica (Ye) serotypes distribution. In biotypes 1A and 1B, the most frequent serotype was O:8, followed by O:5. The biotype 2 was represented by a single not-typable sample. However, in all biotypes (1A, 1B and 2) an elevated percentage of serotypes was found not-typable (31.69%, 50% and 100%, respectively).
Distribution of virulence genes among Y. enterocolitica isolates. Not-typable (NT). +: virulence genes positive.
| Bio/Serotype (Number) | Virulence Genes | |||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| 1A/O:8 (46) | +(31/126) | +(8/126) | +(36/126) | +(5/126) | +(27/126) | +(8/126) |
| 1A/O:5 (12) | +(6/126) | +(1/126) | +(7/126) | +(2/126) | +(6/126) | +(2/126) |
| 1A/O:9 (11) | +(9/126) | +(5/126) | +(10/126) | +(1/126) | +(9/126) | +(2/126) |
| 1A/O:3 (8) | +(3/126) | +(3/126) | +(5/126) | (0/126) | +(4/126) | (0/126) |
| 1A/O:1,2 (3) | (0/126) | (0/126) | +(1/126) | (0/126) | (0/126) | (0/126) |
| 1A/NT (37) | +(4/126) | +(6/126) | +(21/126) | +(2/126) | +(6/126) | +(2/126) |
| 1B/O:5 (1) | +(0/126) | +(1/126) | +(1/126) | (0/126) | +(1/126) | (0/126) |
| 1B/O:8 (2) | +(1/126) | (0/126) | +(1/126) | (0/126) | +(1/126) | (0/126) |
| 1B/O:1.2 (1) | (0/126) | (0/126) | +(1/126) | (0/126) | +(1/126) | (0/126) |
| 1B/NT (4) | +(1/126) | (0/126) | +(4/126) | (0/126) | +(1/126) | +(1/126) |
| 2/NT (1) | (0/126) | +(1/126) | +(1/126) | (0/126) | +(1/126) | (0/126) |
Percentage of pathogenicity genes in bio-serotyped (BT) 1A, 1B and 2 isolates.
| Pathogenicity Genes | ||||||
|---|---|---|---|---|---|---|
|
|
|
|
| ymoA | myfA | |
| Total | 43.6 | 19.8 | 69.8 | 7.9 | 45.2 | 11.9 |
| 1B | 42.06 | 18.25 | 63.49 | 7.9 | 41.27 | 11.11 |
| 1A | 1.58 | 0.79 | 5.55 | 0 | 3.17 | 0.79 |
| 2 | 0 | 0.79 | 0.79 | 0 | 0.79 | 0 |
Percentage of antibiotic resistance showed by Ye isolates analyzed from 2013 to 2018.
| Antibiotic | Percentage of Antibiotic Resistance |
|---|---|
| Chloramphenicol | 0 |
| Enrofloxacin | 0 |
| Gentamycin | 1.58 |
| Kanamycin | 1.58 |
| Streptomycin | 0.79 |
| Sulfamethoxazole Trimethoprim | 3.17 |
| Tetracycline | 0.79 |
Percentage of antibiotic resistance to the reported drugs during the year considered in the study.
| Antibiotic | Percentage of Antibiotic Resistance 2013–2018 | |||
|---|---|---|---|---|
| 2014 | 2015 | 2016 | 2017 | |
| Ampicillin | 21 | 26 | 43 | 18 |
| Ceftiofur | 0 | 6.6 | 12.9 | 0 |
| Sulfisoxazole | 4.5 | 20 | 29.6 | 35 |
| Triple-Sulfa | 0 | 13.3 | 35.1 | 35 |
Percentage of strains showing antibiotic multi-resistance (MRS) increase ina time-dependent manner.
| Years | MRS Percentage |
|---|---|
| 2014 | 9.5 |
| 2015 | 30 |
| 2016 | 38.1 |
| 2017 | 40 |
Percentage of MRS in Ye isolates considering pair of drugs.
| Drugs | 2014 | 2015 | 2016 | 2017 |
|---|---|---|---|---|
| Ampicillin + Ceftiofur | 0 | 6.6 | 13 | 0 |
| Ampicillin + Triple-Sulfa | 0 | 13.3 | 35.1 | 35 |
| Ampicillin + Sulfisoxazole | 4.5 | 16.6 | 39.6 | 35 |
Primer Set for Real-Time Polymerase Chain Reaction Amplification.
| Gene | Primer | Product Length (bp) | Accession Number | Source | |
|---|---|---|---|---|---|
|
| Forward | TGCCTTGGTATGACTCTGCTTCA | 1144 | X53368 | 23 |
| Reverse | AGCGCACCATTACTGGTGGTTAT | Z48169 | |||
|
| Forward | CAGATACACCTGCCTTCCATCT | 271 | Z21953 | 61 |
| Reverse | CTCGACATATTCCTCAACACGC | ||||
|
| Forward | GACTTTTCTCAGGGGAATAC | 329 | X58058 | 62 |
| Reverse | GCTCAACGTTGTGTGTCT | AY387659 | |||
|
| Forward | TAATGTGTACGCTGCGAG | 54 | JX972143 | 45 |
| Reverse | GACGTCTTACTTGCACTG | JQ665437 | |||
|
| Forward | ATCGACACCAATAACCGCTGAG | 78 | X65999 | 63 |
| Reverse | CCAATCACTACTGACTTCGGCT | X65999 | |||
|
| Forward | GTACATTAGGCCAAGAGACG | 145 | KM253278 | 63 |
| Reverse | GCAACATACCTCACAACACC | KM253279 | |||